Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936180 | 1.00 | IRAK4 (0.39) | IRAK4NPC1PKMMAPK1PDPK1 | |
| SCHEMBL30035092 | 0.80 | NPC1 (0.35) | NPC1PKMMAPK1PDPK1 | |
| SCHEMBL657295 | 0.77 | IRAK4 (0.37) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL21371622 | 0.77 | IRAK4 (0.37) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL30679394 | 0.77 | IRAK4 (0.37) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL4302108 | 0.75 | IRAK4 (0.39) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL24375572 | 0.75 | IRAK4 (0.39) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL22430212 | 0.75 | IRAK4 (0.36) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL10254362 | 0.75 | IRAK4 (0.51) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL18238075 | 0.75 | IRAK4 (0.37) | IRAK4MAP3K7AURKAFLT3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | claimed |
| WO-2009013545-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | claimed |
| EP-0452002-A2 | Thienopyrimidine derivatives | DOWELANCO (US) | 1991-10-16 | — | — | EP | claimed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023018699-A1 | SELECTIVE KRAS INHIBITORS | ERASCA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-3642199-B1 | BENZOFURANS AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-10899772-B2 | IRAK4 modulators | GENENTECH, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3642201-A1 | ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20200115383-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| EP-3617213-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2020-03-04 | — | — | EP | disclosed |
| CN-110785418-A | Isoindolinone derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-02-11 | — | — | CN | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-7285556-B2 | Thienopyrimidine-based inhibitors of the src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-0452002-A2 | Thienopyrimidine derivatives | DOWELANCO (US) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | IRAK4 3191/4885NPC1 869/4885PKM 2877/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | IRAK4 185/4885NPC1 3106/4885PKM 750/4885 |
| US-20200115383-A1 | IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885NPC1 1149/4885PKM 1370/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | IRAK4 2715/4885NPC1 1470/4885PKM 4672/4885 |
| US-10899772-B2 | IRAK4 modulators | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885NPC1 1149/4885PKM 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.